BHVN Stock Summary and Trading Ideas (Biohaven Ltd. Common Shares | NYSE:BHVN)

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Biohaven Ltd. Common Shares trades on the NYSE stock market under the symbol BHVN.

As of April 25, 2024, BHVN stock price declined to $38.54 with 1,765,192 million shares trading.

BHVN has a beta of 1.92, meaning it tends to be more sensitive to market movements. BHVN has a correlation of 0.08 to the broad based SPY ETF.

BHVN has a market cap of $3.40 billion. This is considered a Mid Cap stock.

In the last 3 years, BHVN stock traded as high as $152.56 and as low as $7.10.

The top ETF exchange traded funds that BHVN belongs to (by Net Assets): VTI, VB, IWM, VBR, VXF.

BHVN has outperformed the market in the last year with a return of +177.9%, while the SPY ETF gained +23.6%. However, in the most recent history, BHVN shares have underperformed the stock market with its stock returning -15.5% in the last 3 month period and -24.5% for the last 2 week period, while SPY has returned +4.1% and -2.1%, respectively.

BHVN support price is $36.99 and resistance is $40.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BHVN stock will trade within this expected range on the day.